#### **EMWA Newsblast- November 2020**

EMWA Virtual Conference 4 - 19 November 2020



\*|MC:TOC|\*

#### **EMWA 50th Conference**

The first 3 days of EMWA's first virtual conference are over! It was a big accomplishment for a membership-driven organization! We had more than 300 registrants from 27 countries, 5 different continents, who joined the very first EMWA Virtual Conference. The opening session had 180 participants who almost made us feel like the usual face-to-face conferences!

Until the 19th of November we are running fully-booked workshops, smoothly and successful with the help of all volunteers who make these workshops possible. We wish you the best with the workshops and hope to see you all face-to-face in the near future!

#### **EMWA 8th Symposium**

The 8th EMWA Symposium brought together a diverse and international range of stakeholders to address the significant challenges around research integrity and the role of the medical communicator.

This was a highly practical series of practice-based presentations that will better equip medical communicators to add value to their work. Critical to success in improving research integrity is increasing trust, transparency and open research.

A culture of change is also required across all stakeholders and which the Symposium Faculty identified as a significant challenge. COVID-19 has only amplified a long-standing problem of pressure to publish too quickly but, to quote one of the Faculty, we need to ensure that we only "operate at the speed of science".

### Virtual ESS Save the Date

How does RWE impact medical publishing and medical writers? What are the current trends, practices, and guidelines in disseminating RWE? How do stakeholders across the board process RWE to ensure data quality?

Join us for EMWA's virtual Expert Seminar Series on Medical Communications, on the 1st of December, 13:30-16:30 CET. More details on the programme and registration procedure coming soon!

### **2021 European Meeting of ISMPP**

Our friends at ISMPP invite EMWA members to attend their 2021 virtual European Meeting. Registration is now open.

Please contact <u>Head Office</u> for details on discount code.

#### Serbian Translation Joint Position Statement on

#### **Predatory Journals**

We are proud to announce the posting of the JPS translation into Serbian by Katarina Ludajic and Ksenija Vasilic.

In order to access the translation please click <u>here</u>.

We are currently looking for translators. If you would like to volunteer please contact Abe Shevack or the EMWA Head Office.

### **Ambassador's Programme**

If you are an experienced medical writer and EMWA volunteer and are interested in becoming an EMWA Ambassador or if you know of any upcoming career events in your locality please contact Head Office or Abe Shevack.

## **Webinar Programme News**

Thursday January 21st 2021, 14:00 CET

**Publication Planning** By Andrea Rossi - Medical writing, medical communications and scientific

affairs consultant, and Julia Donnelly - Medical communications consultant In this webinar the key aspects and challenges of Publication Planning will be

explored to give insight on what publication planning is, the importance of a good publication planning and how medical writers who are working on the preparation of high-impact publications, can help to deliver a successful publication plan. With the right focus and planning, you can choose the right targets to achieve your writing goals. Basic know-how of the environment of scientific publications and clinical studies disclosure is needed to fully appreciate the contents.

## For Here is Bespoke Windbagerry: Vacate the Hall, and the Podium too, by

New web editorial online

Jack Aslanian.

To read the full article, click <u>here</u>.

# **Regulatory News**

**COVID-19** related news:

Click <u>here</u> to read this month's Pharmacovigilance SIG news:

### New FDA EUA guidance for COVID-19 vaccines

- Remdesivir received FDA approval for COVID-19 treatment The CHMP started two rolling reviews for two potential vaccines for
- COVID-19 The EMA received the application for marketing authorisation of
- Dexamethasone Taw for COVID-19 Other news:
  - reporting TransCelerate Biopharma has a new page dedicated to the Interpretation

With new draft guidance, the FDA moves towards uniform post-marketing

IME (Important Medical Events) list updated with inclusion/exclusion

- of Pharmacovigilance Guidances and Regulations Solutions The IMDRF proposed updates to its guidance on post-marketing clinical follow-up for medical devices
- EMA guideline on registry-based studies launch of public consultation

Cheshire SK11 6DY, United Kingdom

Registered Office: Chester House, 68 Chestergate, Macclesfield,



Tel: +44(0)1625 664534 E-mail: info@emwa.org A Private Limited Company registered in England and Wales No: 03653609 Confidentiality Note: Please note that this e-mail and any files transmitted with it are intended for the use of the addressee only and may contain confidential and/or privileged information. If the reader of this e-

mail is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that reading this e-mail is strictly prohibited. If you have received this email in error, please immediately return it to the sender and delete it from your system. This e-mail, and any attachments, has been checked by us for computer viruses. Although none have been detected we cannot guarantee that it is completely free from such problems and we do not accept any liability for loss or damage that may be caused. We would therefore advise you to carry out your own virus checks before opening any attachments. A copy of the EMWA Privacy policy can be found <u>here</u> Copyright © 2020, All rights reserved.

> Want to change how you receive these emails? You can <u>update your preferences</u> or <u>unsubscribe from this list</u>

\*|LIST:ADDRESSLINE|\*